[go: up one dir, main page]

ATE455554T1 - Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen - Google Patents

Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen

Info

Publication number
ATE455554T1
ATE455554T1 AT02011474T AT02011474T ATE455554T1 AT E455554 T1 ATE455554 T1 AT E455554T1 AT 02011474 T AT02011474 T AT 02011474T AT 02011474 T AT02011474 T AT 02011474T AT E455554 T1 ATE455554 T1 AT E455554T1
Authority
AT
Austria
Prior art keywords
compositions
lean meat
meat mass
increase lean
obesity protein
Prior art date
Application number
AT02011474T
Other languages
English (en)
Inventor
Mary Ann Pelleymounter
Christopher Francis Toombs
Michael Benjamin Mann
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE455554T1 publication Critical patent/ATE455554T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02011474T 1995-11-22 1996-11-04 Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen ATE455554T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22

Publications (1)

Publication Number Publication Date
ATE455554T1 true ATE455554T1 (de) 2010-02-15

Family

ID=24243198

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96938773T ATE259243T1 (de) 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
AT02011474T ATE455554T1 (de) 1995-11-22 1996-11-04 Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96938773T ATE259243T1 (de) 1995-11-22 1996-11-04 Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse

Country Status (15)

Country Link
EP (3) EP0866720B1 (de)
JP (2) JP4173914B2 (de)
AT (2) ATE259243T1 (de)
AU (3) AU7607496A (de)
CA (2) CA2358862A1 (de)
DE (2) DE69638119D1 (de)
DK (1) DK0866720T3 (de)
ES (2) ES2339846T3 (de)
IL (2) IL124442A0 (de)
MX (1) MX9803992A (de)
NZ (3) NZ511617A (de)
PT (1) PT866720E (de)
SI (1) SI0866720T1 (de)
WO (1) WO1997018833A1 (de)
ZA (1) ZA969605B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
ATE259243T1 (de) * 1995-11-22 2004-02-15 Amgen Inc Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
JP2000509377A (ja) * 1996-04-19 2000-07-25 ザイモジェネティクス，インコーポレイティド 骨形成を誘発するための方法
ES2280083T3 (es) * 1996-12-20 2007-09-01 Amgen Inc. Composiciones de proteinas de fusion ob y metodos.
WO1998028414A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (de) * 1998-02-23 2000-02-23 Pfizer Products Inc. Behandlung von Skeletterkrankungen
WO1999053939A1 (en) * 1998-04-20 1999-10-28 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU1134000A (en) * 1998-10-27 2000-05-15 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
PT1151102E (pt) * 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DK2219031T3 (da) 2001-10-22 2013-06-17 Amgen Inc Anvendelse af leptin til behandling af human lipoatrofi og fremgangsmåde til bestemmelse af prædisposition for behandlinngen
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
HUE040496T2 (hu) 2012-09-27 2019-03-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
LT3074033T (lt) 2013-11-26 2019-02-25 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
FI3509624T3 (fi) 2016-09-12 2023-10-18 Amryt Pharmaceuticals Inc Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
WO1995005309A1 (de) * 1993-08-13 1995-02-23 Putzmeister-Werk Maschinenfabrik Gmbh Verfahren und anordnung zur oberflächenbearbeitung von grossobjekten
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
ATE259243T1 (de) * 1995-11-22 2004-02-15 Amgen Inc Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
AU1520097A (en) * 1995-12-27 1997-07-28 Genentech Inc. Ob protein derivatives having prolonged half-life
ES2280083T3 (es) * 1996-12-20 2007-09-01 Amgen Inc. Composiciones de proteinas de fusion ob y metodos.
AU7132798A (en) * 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Also Published As

Publication number Publication date
DE69638119D1 (de) 2010-03-11
EP0866720A1 (de) 1998-09-30
MX9803992A (es) 1998-09-30
SI0866720T1 (en) 2004-10-31
ES2339846T3 (es) 2010-05-26
PT866720E (pt) 2004-06-30
CA2358862A1 (en) 1997-05-29
EP1285664B1 (de) 2010-01-20
ATE259243T1 (de) 2004-02-15
AU4265300A (en) 2000-09-07
EP0866720B1 (de) 2004-02-11
EP1285664A3 (de) 2003-07-30
AU4265200A (en) 2000-09-21
DK0866720T3 (da) 2004-06-14
ES2217327T3 (es) 2004-11-01
JP2002206000A (ja) 2002-07-23
NZ511617A (en) 2003-08-29
EP0956862A1 (de) 1999-11-17
IL124442A0 (en) 1998-12-06
CA2236163A1 (en) 1997-05-29
AU763755B2 (en) 2003-07-31
NZ527007A (en) 2005-01-28
JP4227325B2 (ja) 2009-02-18
DE69631544D1 (de) 2004-03-18
ZA969605B (en) 1997-06-02
IL127926A (en) 2006-08-20
DE69631544T2 (de) 2004-12-23
AU763769B2 (en) 2003-07-31
JP2000500492A (ja) 2000-01-18
WO1997018833A1 (en) 1997-05-29
IL127926A0 (en) 1999-11-30
EP1285664A2 (de) 2003-02-26
AU7607496A (en) 1997-06-11
JP4173914B2 (ja) 2008-10-29
NZ512083A (en) 2003-02-28

Similar Documents

Publication Publication Date Title
ATE455554T1 (de) Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen
FI963315L (fi) Laite, menetelmä ja apuvälineet ihmisen tai eläimen kova- tai pehmytkudosten ja hampaan tai luun korvaavien materiaalien valmistamiseksi ultraäänen avulla ja siten aikaansaadut kohteet
RO117177B1 (ro) Proteine recombinante, anti-obezitate, murine şi umane, secvenţă adn, care le codifică, procedeu de producere a proteinei şi conjugat cu acestea
DE69022163D1 (de) Steriles erzeugnis und verfahren zur sterilisierung und zusammenbau dieses erzeugnisses.
DK0831884T3 (da) Anvendelse af knoglemorfogenetiske proteiner til heling og reparation af bindevævsbinding
DE60137430D1 (de) Gewebeimplant zur wiederherstellung von knorpelgewebe
ZA951008B (en) N-terminally chemically modificed protein compositions and method
WO1998021972A3 (de) Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender aktivität
ATE510552T1 (de) Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
HUP9901688A3 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
DE69535274D1 (de) Verwendung eines menschlichen interleukin-11 rezeptors
ATE167232T1 (de) Protein mit knochenbildungs-eigenschaften und verfahren zu seiner herstellung
ATE122467T1 (de) Verfahren zur detektion von knochen- und anderen bindegewebeerkrankungen bei menschen und tieren.
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
ATE128872T1 (de) Gesteigerte erzeugung von proteinen in tieren.
SE9803962D0 (sv) Nucleic acid encoding a nervous tissue sodium channel
EP0866654A4 (de) Methode für die behandlung einer hepatitisvirusinfektion
EP0915168A4 (de) Verfahren zur herstellung von knochenreifungsspezifischem, morphogenetischem protein
AU2003202489A1 (en) Screening method
MD899G2 (ro) Procedeu de activizare a osteogenezei reparatorii

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties